AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

DBV Technologies Report Publication Announcement 2017

Apr 5, 2017

1248_iss_2017-04-05_d4b9bca0-87b4-4fda-bab4-c81c5709df17.pdf

Report Publication Announcement

Open in viewer

Opens in your device viewer

Press Release Montrouge, France, April 5, 2017

DBV Technologies to Attend the 10th Kempen Life Sciences Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Senior Vice President, Strategy, will host investor meetings during the 10th Kempen Life Sciences Conference on Wednesday, April 19, 2017, at the Kempen & Co offices in Amsterdam, Netherlands.

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of selfadministered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing onehalf of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

DBV Technologies Contact

Sara Blum Sherman Director, Investor Relations +1 212-271-0740 [email protected]

Media Contact Andrea Fassacesia, Weber Shandwick +1 212-445-8144 [email protected]

Media Contact Europe

Caroline Carmagnol, Alize RP, Relations Presse +33 (0)6 64 18 99 59 [email protected]